ARTICLE | Clinical News
Invega Sustenna: Phase III data
December 14, 2009 8:00 AM UTC
In a 13-week, double-blind, placebo-controlled Phase III trial in 1,220 patients, once-monthly Invega Sustenna met the primary endpoint of non-inferiority to biweekly Risperdal Consta risperidone in d...